Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/16/2017 01/17/2017 01/18/2017 01/19/2017 01/20/2017 Date
72.1(c) 71.35(c) 72.2(c) 71.1(c) 70.9(c) Last
5 289 130 7 199 316 5 392 864 7 945 544 9 811 033 Volume
-1.23% -1.04% +1.19% -1.52% -0.28% Change
More quotes
Financials ($)
Sales 2016 48 745 M
EBIT 2016 11 762 M
Net income 2016 7 987 M
Debt 2016 15 002 M
Yield 2016 3,99%
Sales 2017 49 012 M
EBIT 2017 11 884 M
Net income 2017 8 307 M
Debt 2017 13 828 M
Yield 2017 4,13%
P/E ratio 2016 20,63
P/E ratio 2017 19,65
EV / Sales2016 4,11x
EV / Sales2017 4,06x
Capitalization 185 152 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical, ophthalmic... 
Sector
Pharmaceuticals
Calendar
01/25Earnings Release
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
01/19 NOVARTIS : Patent Issued for Solid Oral Formulations and Crystalline Forms of an..
01/19 NOVARTIS : Patent Issued for MELK Regulation for the Treatment of Breast Cancer ..
01/19 NOVARTIS : Patent Issued for Integrated OCT-Refractometer System for Ocular Biom..
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/18 Drugmakers in Davos shift focus to chronic diseases of poor
01/16 NOVARTIS : invests in next generation therapies to reduce cardiovascular risk in..
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13 NOVARTIS : NICE approves kidney cancer drug for NHS use
01/12 NOVARTIS : "Combination Therapy Comprising an Inhibitor of Jak, Cdk, and Pim" in..
01/12 NOVARTIS : Patent Issued for Pharmaceutical Combination Comprising a Phosphatidy..
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 GSK grabs Astra executive to replace pharma head
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on NOVARTIS AG 
2016A trend reversal can be anticipated
More Strategies
Latest Tweets
03:28aNovartis (NVS) Q4 Earnings: Stock Likely to Disappoint? -  
01/20#NowPlaying Betty Roché - You Don't Love Me No More 
01/20Novartis has agreed three deals in a matter of weeks, acquiring several promi..
1
01/20Novartis CEO: Trump understands the value of drug innovation  
01/20Novartis CEO: Trump understands the value of drug innovation  
More tweets
Qtime:155
News from SeekingAlpha
01/20 The Most Important Keys To Celgene's Pipeline
01/20 FDA Baits Biosimilar Makers With Switching Guidance
01/20 Pharma bigwigs acknowledge challenges with perceptions of pricing as Trump pr..
01/19 MALLINCKRODT POST-FTC SETTLEMENT : Buy The Dip Or Valeant-Lite?
01/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 29
Average target price 79,7 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-4.32%185 152
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
MERCK & CO., INC.6.22%172 404
SANOFI-1.66%104 532
More Results